An overview of foot infections in diabetes

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients with diabetes are prone to ulcerations of the lower extremities, frequently complicated by infection, and are then reliant upon their caregivers for preservation of their limbs without the dreaded outcome of amputation. The enormous tolls of foot infections in diabetes, in terms of both health-related quality of life issues and associated economic burdens, have only been fully realized within the last few decades, and it is anticipated that these burdens will only increase over time. Early and appropriate antibiotic treatment targeting the most likely etiologic pathogens is a cornerstone of management of foot infections in diabetes, but these decisions are now complicated by the emergence of resistant organisms, particularly methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative species. This review will examine the impact of foot infections in diabetes and the overall care and management of the diabetes patient with foot infection, including the potential value of emerging antibiotic therapies within the milieu of antibiotic resistance.

Original languageEnglish (US)
Pages (from-to)951-957
Number of pages7
JournalDiabetes Technology and Therapeutics
Volume13
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

Foot
Infection
Patient Care Management
Anti-Bacterial Agents
Methicillin-Resistant Staphylococcus aureus
Microbial Drug Resistance
Amputation
Caregivers
Lower Extremity
Extremities
Economics
Quality of Life
Therapeutics

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medical Laboratory Technology

Cite this

An overview of foot infections in diabetes. / Armstrong, David G.

In: Diabetes Technology and Therapeutics, Vol. 13, No. 9, 01.09.2011, p. 951-957.

Research output: Contribution to journalArticle

@article{0038c248bb474edbaabed7dd69f22c68,
title = "An overview of foot infections in diabetes",
abstract = "Patients with diabetes are prone to ulcerations of the lower extremities, frequently complicated by infection, and are then reliant upon their caregivers for preservation of their limbs without the dreaded outcome of amputation. The enormous tolls of foot infections in diabetes, in terms of both health-related quality of life issues and associated economic burdens, have only been fully realized within the last few decades, and it is anticipated that these burdens will only increase over time. Early and appropriate antibiotic treatment targeting the most likely etiologic pathogens is a cornerstone of management of foot infections in diabetes, but these decisions are now complicated by the emergence of resistant organisms, particularly methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative species. This review will examine the impact of foot infections in diabetes and the overall care and management of the diabetes patient with foot infection, including the potential value of emerging antibiotic therapies within the milieu of antibiotic resistance.",
author = "Armstrong, {David G}",
year = "2011",
month = "9",
day = "1",
doi = "10.1089/dia.2011.0007",
language = "English (US)",
volume = "13",
pages = "951--957",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - An overview of foot infections in diabetes

AU - Armstrong, David G

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Patients with diabetes are prone to ulcerations of the lower extremities, frequently complicated by infection, and are then reliant upon their caregivers for preservation of their limbs without the dreaded outcome of amputation. The enormous tolls of foot infections in diabetes, in terms of both health-related quality of life issues and associated economic burdens, have only been fully realized within the last few decades, and it is anticipated that these burdens will only increase over time. Early and appropriate antibiotic treatment targeting the most likely etiologic pathogens is a cornerstone of management of foot infections in diabetes, but these decisions are now complicated by the emergence of resistant organisms, particularly methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative species. This review will examine the impact of foot infections in diabetes and the overall care and management of the diabetes patient with foot infection, including the potential value of emerging antibiotic therapies within the milieu of antibiotic resistance.

AB - Patients with diabetes are prone to ulcerations of the lower extremities, frequently complicated by infection, and are then reliant upon their caregivers for preservation of their limbs without the dreaded outcome of amputation. The enormous tolls of foot infections in diabetes, in terms of both health-related quality of life issues and associated economic burdens, have only been fully realized within the last few decades, and it is anticipated that these burdens will only increase over time. Early and appropriate antibiotic treatment targeting the most likely etiologic pathogens is a cornerstone of management of foot infections in diabetes, but these decisions are now complicated by the emergence of resistant organisms, particularly methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative species. This review will examine the impact of foot infections in diabetes and the overall care and management of the diabetes patient with foot infection, including the potential value of emerging antibiotic therapies within the milieu of antibiotic resistance.

UR - http://www.scopus.com/inward/record.url?scp=80052060286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052060286&partnerID=8YFLogxK

U2 - 10.1089/dia.2011.0007

DO - 10.1089/dia.2011.0007

M3 - Article

C2 - 21631279

AN - SCOPUS:80052060286

VL - 13

SP - 951

EP - 957

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 9

ER -